{"id":51259,"date":"2025-04-14T16:11:39","date_gmt":"2025-04-14T16:11:39","guid":{"rendered":"https:\/\/www.fomatmedical.com\/?p=51259"},"modified":"2026-04-17T16:00:41","modified_gmt":"2026-04-17T23:00:41","slug":"endocrine-related-cancers-trials","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/endocrine-related-cancers-trials\/","title":{"rendered":"Los obst\u00e1culos y las promesas en los c\u00e1nceres relacionados con el sistema endocrino"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"51259\" class=\"elementor elementor-51259\" wpc-filter-elementor-widget=\"1\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-8286ec3 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"8286ec3\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7af31a0\" data-id=\"7af31a0\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-702b7a0 elementor-widget elementor-widget-text-editor\" data-id=\"702b7a0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Cancer is a complicated disease and research is constantly changing our understanding of it. One of the latest is endocrine-related cancers (ERCs), cancers driven by hormones. Breast and prostate cancer have been hormone-driven for ages, but research is showing hormones may be involved in many other cancers, too.<\/span><\/p><p><span style=\"font-weight: 400;\">This opens up new possibilities for treatment, especially through clinical endocrinology trials. These trials are developing therapies that target the hormonal factors that drive cancer growth. But this progress also brings challenges like treatment resistance and the need for better diagnostic tools.<\/span><\/p><p><span style=\"font-weight: 400;\">Let\u2019s get into what endocrine-related cancers are, why more cancers are now considered hormone-driven, the challenges in cancer endocrinology and the future of hormone-targeted treatments.<\/span><\/p><h2><span style=\"font-weight: 400;\">What Are Endocrine-Related Cancers?<\/span><\/h2><p><span style=\"font-weight: 400;\">Endocrine-related cancers are cancers influenced by hormones that control many of our body\u2019s functions. Some of the most well-known ERCs are:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.fomatmedical.com\/patient-active-studies\/?filters=product_cat[1038]#activestudies\"><b>Breast cancer<\/b><\/a><span style=\"font-weight: 400;\"> (driven by estrogen and progesterone in many cases)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Prostate cancer<\/b><span style=\"font-weight: 400;\"> (influenced by testosterone and other androgens)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Thyroid cancer<\/b><span style=\"font-weight: 400;\"> (affects the gland that controls metabolism)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Ovarian and endometrial cancers<\/b><span style=\"font-weight: 400;\"> (linked to estrogen)<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Adrenal cancer<\/b><span style=\"font-weight: 400;\"> (originates in glands that produce stress and metabolism-related hormones)<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">These cancers have been the focus of research because of the strong link to hormones. But newer research is showing even cancers outside this group, like liver, kidney and lung cancers, may be hormone-driven making ERCs an expanding field of research.<\/span><\/p><h2><span style=\"font-weight: 400;\">The Surprising Link Between Hormones and Lung Cancer<\/span><\/h2><p><span style=\"font-weight: 400;\">Lung cancer has always been associated with smoking but research is uncovering a new trend. Non-smoking women were found to develop lung cancer at higher rates than expected. A study found estrogen receptors in lung tumors, so hormonal factors might be involved. This led to clinical trials testing estrogen-blocking therapies for lung cancer, an alternative to traditional chemotherapy.<\/span><\/p><h2><span style=\"font-weight: 400;\">The Growing Understanding of Endocrine-Related Cancers<\/span><\/h2><p><span style=\"font-weight: 400;\">We\u2019ve known for years that hormones produced by our bodies can impact cancer development. Research has shown hormones like estrogen, testosterone and insulin can increase cancer risk. For example:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Women with prolonged estrogen exposure (early menstruation, late menopause, hormone replacement therapy) have a higher risk of breast and endometrial cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Men with high androgen levels are at higher risk for aggressive prostate cancer.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Insulin resistance, often caused by obesity, has been linked to an increased risk of colon, pancreatic and liver cancers.<\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">As we learn more about these links, the definition of endocrine-related cancers is expanding. This means cancers once thought to be unrelated to hormones may actually be hormone-driven. So, new endocrine-based treatments are being tested in clinical endocrinology trials.<\/span><\/p><h2><span style=\"font-weight: 400;\">Overcoming the Challenges in Endocrine-Related Cancer Research<\/span><\/h2><p><span style=\"font-weight: 400;\">While recognition of hormone-driven cancers offers new hope for targeted treatments, there are several challenges. These include difficulty in diagnosing hormone-sensitive cancers, overcoming treatment resistance and filling in the research gaps. Ethical concerns in clinical trials and accessibility issues add to the hurdles.<\/span><\/p><h3><span style=\"font-weight: 400;\">1. Diagnosis and Classification<\/span><\/h3><p><span style=\"font-weight: 400;\">One of the biggest challenges in endocrine-related cancers is to determine which cancers are truly hormone-driven. While some cancers like breast and prostate cancer have clear hormonal links, others like lung and liver cancer are still being studied to understand the role of hormones. Many cancers have multiple causes, including genetic and hormonal factors.<\/span><\/p><p><span style=\"font-weight: 400;\">New diagnostic tools are being developed to improve the accuracy of diagnosing hormone-driven cancers. Liquid biopsies, which analyze cancer-related DNA from a blood sample, will help detect hormone-sensitive cancers earlier and more precisely. AI-driven imaging techniques are also being explored to help doctors analyze tumors better. However, getting an accurate diagnosis remains a challenge in cancer endocrinology.<\/span><\/p><h3><span style=\"font-weight: 400;\">2. Treatment Resistance<\/span><\/h3><p><span style=\"font-weight: 400;\">Hormone therapies have improved the treatment of endocrine-related cancers. Drugs like tamoxifen for breast cancer and androgen-blocking medications for prostate cancer have led to better survival rates. But many cancers develop resistance to these treatments and the disease progresses and patients have fewer options. Treatment resistance happens when the tumors adapt and find new ways to grow, even when the hormones are blocked. <\/span><\/p><p>For example, in some breast cancer patients, the cancer cells may change the estrogen receptors or use other growth pathways and anti-estrogen drugs become ineffective. Similarly, in prostate cancer, some aggressive tumors start producing their own androgens and continue to grow despite hormone therapy. Researchers are developing a new generation of hormone therapies to address this issue.<\/p><p>For example, selective estrogen receptor degraders (SERDs) are being tested to destroy estrogen receptors in breast cancer instead of just blocking them. In prostate cancer, new androgen receptor inhibitors are being developed to target alternative pathways the tumors use to bypass treatment. Combination therapies that pair hormone therapy with chemotherapy or immunotherapy are also being tested to prevent resistance from developing.<\/p><p><span style=\"font-weight: 400;\">Personalized treatment plans that use genetic testing to understand how a patient\u2019s cancer may develop resistance are becoming more common. Identifying the mutations that contribute to resistance allows doctors to adjust treatment in real-time and improve patient outcomes.<\/span><\/p><h3><span style=\"font-weight: 400;\">3. Research Gaps and Ethical Concerns<\/span><\/h3><p><span style=\"font-weight: 400;\">More research is needed to confirm if hormones play a role in cancers that are considered non-endocrine cancers.<\/span><\/p><p><span style=\"font-weight: 400;\">Some endocrine therapies have significant side effects, so we need to balance their effectiveness with patient safety.<\/span><\/p><p><span style=\"font-weight: 400;\">Funding for endocrinology clinical trials needs to increase to support new discoveries.<\/span><\/p><h2><span style=\"font-weight: 400;\">Innovations and Promising Directions for the Future of Cancer Care<\/span><\/h2><p><span style=\"font-weight: 400;\">Despite the challenges, exciting developments in cancer treatment are on the horizon. Some of the most promising include:<\/span><\/p><h3><span style=\"font-weight: 400;\">1. Advanced Hormone Targeted Therapies<\/span><\/h3><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Selective estrogen receptor degraders (SERDs) are a new class of drugs that target and destroy estrogen receptors in breast cancer cells.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Next-generation androgen receptor inhibitors are designed to help patients with resistant prostate cancer by targeting other pathways the tumors use to grow.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Insulin-modulating therapies such as diabetes drugs like metformin are being researched for their cancer-fighting effects.<\/span><\/li><\/ul><h3><span style=\"font-weight: 400;\">2. Precision Medicine and Biomarker Testing<\/span><\/h3><p><span style=\"font-weight: 400;\">Doctors are increasingly using genetic and biomarker tests to personalize hormone therapies for individual patients. This reduces unnecessary treatments and ensures hormone-targeted therapies are used where they will be most effective.<\/span><\/p><h3><span style=\"font-weight: 400;\">3. Breakthroughs in Early Detection<\/span><\/h3><p><span style=\"font-weight: 400;\">Liquid biopsies (blood tests that detect cancer-related DNA) will soon allow for earlier detection of ERCs than traditional methods like imaging or biopsies. AI driven diagnostic tools are also being developed to track hormone fluctuations and predict cancer risk.<\/span><\/p><h3><span style=\"font-weight: 400;\">4. Endocrinology Clinical Trials<\/span><\/h3><p><span style=\"font-weight: 400;\">Clinical trials help researchers develop new hormone-based drugs, combination therapies and personalized treatment approaches and ultimately improve patient outcomes. Many breakthroughs in treating endocrine-related cancers, like tamoxifen for breast cancer or androgen deprivation therapy for prostate cancer, came from clinical trials. Patients who participate in these trials get access to new treatments before they become widely available. However, barriers like geographic limitations, financial challenges, and lack of awareness make it harder for some patients to participate in clinical trials. We need to increase access to these trials so more patients, regardless of their circumstances, can benefit from the latest hormone-targeted therapies.<\/span><\/p><h2><span style=\"font-weight: 400;\">The Path Forward in Cancer Care Through Endocrinology Clinical Trials<\/span><\/h2><p><span style=\"font-weight: 400;\">Endocrine-related cancers are a growing field, with new discoveries expanding our understanding of hormone-driven cancers and treatment options. While challenges like treatment resistance and better diagnostics still exist, research is bringing hope for more effective and personalized treatments.<\/span><\/p><p><span style=\"font-weight: 400;\">Endocrinology clinical trials are key to this progress. These trials help researchers develop new therapies and refine existing treatments and bring us closer to a future where hormone-driven cancers can be detected earlier, treated better and potentially prevented.<\/span><\/p><p><span style=\"font-weight: 400;\">If you or a loved one has a cancer diagnosis, staying informed about hormone-related treatments and <\/span><a href=\"https:\/\/www.fomatmedical.com\/patient-active-studies\/\"><span style=\"font-weight: 400;\">clinical trials could bring new treatment options<\/span><\/a><span style=\"font-weight: 400;\">. Cancer care is moving fast and the outlook is bright for those looking for better treatment options.<\/span><\/p><p><b>References:<\/b><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Henderson, B. E., Ross, R. K., Pike, M. C., &amp; Casagrande, J. T. (1982). Endogenous hormones as a major factor in human cancer. <\/span><i><span style=\"font-weight: 400;\">Cancer Research, 42<\/span><\/i><span style=\"font-weight: 400;\">(8), 3232-3239.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lamberts, S. W., Hofland, L. J., &amp; de Herder, W. W. (2013). Grand Challenges in Cancer Endocrinology: Endocrine-Related Cancers, an Expanding Concept. <\/span><i><span style=\"font-weight: 400;\">Frontiers in Endocrinology, 4<\/span><\/i><span style=\"font-weight: 400;\">, 141. <\/span><a href=\"https:\/\/doi.org\/10.3389\/fendo.2013.00141\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/doi.org\/10.3389\/fendo.2013.00141<\/span><\/a><\/li><li style=\"font-weight: 400;\" aria-level=\"1\">Stabile, L. P., Dacic, S., Land, S. R., Lenzner, D. E., Musunuru, H. B., Anderson, M. J., &amp; Siegfried, J. M. (2002). <i>Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome<\/i>. <i>Clinical Cancer Research, 8<\/i>(4), 1243-1249.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>El c\u00e1ncer es una enfermedad compleja y las investigaciones est\u00e1n cambiando constantemente nuestra comprensi\u00f3n de la misma. Una de las \u00faltimas novedades son los c\u00e1nceres relacionados con el sistema endocrino (ERC), c\u00e1nceres impulsados por las hormonas. El c\u00e1ncer de mama y el de pr\u00f3stata han estado impulsados por las hormonas durante mucho tiempo, pero las investigaciones est\u00e1n demostrando que las hormonas pueden...<\/p>","protected":false},"author":3,"featured_media":51266,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[968],"tags":[],"class_list":["post-51259","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/51259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=51259"}],"version-history":[{"count":7,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/51259\/revisions"}],"predecessor-version":[{"id":86308,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/51259\/revisions\/86308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/51266"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=51259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=51259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=51259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}